SCHEMBL30206349

SCHEMBL30206349

CNc1nc(Nc2ccc(N3CCOCC3)c(F)c2F)c(C(=O)OC)nc1-c1cncc2c1ncn2C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 17/20 0.36
▸ ZAP70 P43403 1/20 0.35
▸ TTK P33981 1/20 0.34
▸ JAK2 O60674 2/20 0.33
▸ MKNK2 Q9HBH9 2/20 0.33
▸ MAP3K9 P80192 1/20 0.33
▸ PTK2 Q05397 2/20 0.32
▸ CDC7 O00311 1/20 0.32
▸ PLK4 O00444 1/20 0.32
▸ CHEK1 O14757 1/20 0.32
▸ AURKA O14965 1/20 0.32
▸ DCLK1 O15075 1/20 0.32
▸ PDPK1 O15530 1/20 0.32
▸ DAPK3 O43293 1/20 0.32
▸ DYRK3 O43781 1/20 0.32
▸ PRKD3 O94806 1/20 0.32
▸ PAK4 O96013 1/20 0.32
▸ CHEK2 O96017 1/20 0.32
▸ EGFR P00533 1/20 0.32
▸ ERBB2 P04626 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29173428 1.00 LRRK2 (0.36) LRRK2ZAP70TTKJAK2MKNK2
SCHEMBL29173615 0.94 LRRK2 (0.35) LRRK2ZAP70TTKJAK2MKNK2
SCHEMBL30205976 0.94 LRRK2 (0.35) LRRK2ZAP70TTKJAK2MKNK2
SCHEMBL30206108 0.94 ZAP70 (0.36) LRRK2ZAP70TTKJAK2MKNK2
SCHEMBL29173545 0.94 ZAP70 (0.36) LRRK2ZAP70TTKJAK2MKNK2
SCHEMBL24944442 0.92 RET (0.37) LRRK2ZAP70PLK4AURKAEGFR
SCHEMBL29173445 0.89 ZAP70 (0.43) LRRK2ZAP70JAK2MKNK2PTK2
SCHEMBL30206248 0.89 LRRK2 (0.37) LRRK2ZAP70EGFRMAPK9MAPK10
SCHEMBL29173569 0.89 LRRK2 (0.37) LRRK2ZAP70EGFRMAPK9MAPK10
SCHEMBL29173530 0.88 LRRK2 (0.37) LRRK2ZAP70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP disclosed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 — — US disclosed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PDXK, PGK1, PGK2 LRRK2 3283/4885ZAP70 560/4885TTK 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback